Effectiveness of a multistep Pseudomonas aeruginosa eradication treatment protocol in children with cystic fibrosis in Brazil
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
Citação
JORNAL BRASILEIRO DE PNEUMOLOGIA, v.46, n.4, article ID e20180294, 6p, 2020
Resumo
Objective: Although various strategies have been proposed for eradicating Pseudomonas aeruginosa in patients with cystic fibrosis (CF), only a few employ multistep treatment in children colonized by that pathogen for the first time. The aim of this study was to describe the effectiveness of a three-phase eradication protocol, initiated after the first isolation of P. aeruginosa, in children with CF in Brazil. Methods: This was a retrospective real-life study in which we reviewed the medical records of pediatric CF patients in whom the eradication protocol was applied between June of 2004 and December of 2012. The three-phase protocol was guided by positive cultures for P. aeruginosa in airway secretions, and the treatment consisted of inhaled colistimethate and oral ciprofloxacin. Success rates were assessed after each phase, as well as cumulatively. Results: During the study period, 47 episodes of P. aeruginosa colonization, in 29 patients, were eligible for eradication. Among the 29 patients, the median age was 2.7 years, 17 (59%) were male, and 19 (65%) had at least one F508del allele. All 29 patients completed the first phase of the protocol, whereas only 12 and 6 completed the second and third phases, respectively. Success rates for eradication in the three treatment phases were 58.6% (95% CI: 40.7-74.5), 50.0% (95% CI: 25.4-74.6), and 66.7% (95% CI: 30.0-90.3), respectively. The cumulative success rate was 93.1% (95% CI: 78.0-98.1). Treatment failure in all three phases occurred in only 2 patients. Conclusions: In this sample of patients, the multistep eradication protocol was effective and had a high success rate.
Palavras-chave
Cystic fibrosis/therapy, Cystic fibrosis/prevention & control, Pseudomonas aeruginosa, Treatment outcome
Referências
- Athanazio RA, 2017, J BRAS PNEUMOL, V43, P219, DOI [10.1590/s1806-37562017000000065, 10.1590/S1806-37562017000000065]
- Blanchard AC, 2017, J CYST FIBROS, V16, P395, DOI 10.1016/j.jcf.2017.01.007
- Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O
- Hewer SCL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004197.pub5
- Li ZH, 2005, JAMA-J AM MED ASSOC, V293, P581, DOI 10.1001/jama.293.5.581
- LITTLEWOOD JM, 1985, LANCET, V1, P865, DOI 10.1016/S0140-6736(85)92222-6
- Mayer-Hamblett N, 2015, CLIN INFECT DIS, V61, P707, DOI 10.1093/cid/civ377
- Proesmans M, 2013, J CYST FIBROS, V12, P29, DOI 10.1016/j.jcf.2012.06.001
- Ratjen F, 2010, THORAX, V65, P286, DOI 10.1136/thx.2009.121657
- Schelstraete P, 2013, J CYST FIBROS, V12, P1, DOI 10.1016/j.jcf.2012.07.008
- SHWACHMAN H, 1958, AMA J DIS CHILD, V96, P6, DOI 10.1001/archpedi.1958.02060060008002
- Taccetti G, 2005, EUR RESPIR J, V26, P458, DOI 10.1183/09031936.05.00009605
- Taccetti G, 2012, THORAX, V67, P853, DOI 10.1136/thoraxjnl-2011-200832
- Treggiari MM, 2011, ARCH PEDIAT ADOL MED, V165, P847, DOI 10.1001/archpediatrics.2011.136
- VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2
- World Health Organization, WHO ANTHR SURV AN OT